Nordea Investment Management AB Has $885.25 Million Stock Holdings in McKesson Corporation $MCK

Nordea Investment Management AB decreased its holdings in shares of McKesson Corporation (NYSE:MCK) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,071,733 shares of the company’s stock after selling 21,798 shares during the period. McKesson comprises 0.8% of Nordea Investment Management AB’s portfolio, making the stock its 25th biggest holding. Nordea Investment Management AB owned about 0.87% of McKesson worth $885,251,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of McKesson during the 2nd quarter worth approximately $1,346,661,000. Alliancebernstein L.P. grew its position in McKesson by 150.4% in the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock valued at $1,661,956,000 after acquiring an additional 1,362,386 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in McKesson by 56.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock worth $906,109,000 after acquiring an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in McKesson by 45.6% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after acquiring an additional 261,296 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of McKesson by 34.1% during the second quarter. The Manufacturers Life Insurance Company now owns 839,690 shares of the company’s stock valued at $615,305,000 after acquiring an additional 213,406 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of McKesson from a “hold” rating to a “buy” rating in a report on Sunday. Evercore reissued an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Raymond James Financial set a $970.00 price target on shares of McKesson in a research report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Finally, Barclays raised their price objective on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, McKesson currently has an average rating of “Moderate Buy” and an average price target of $960.93.

Insiders Place Their Bets

In related news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the transaction, the director owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,868 shares of company stock valued at $3,743,820 over the last quarter. Company insiders own 0.08% of the company’s stock.

McKesson Stock Down 1.2%

McKesson stock opened at $888.28 on Friday. The stock has a 50-day simple moving average of $903.68 and a 200 day simple moving average of $833.49. The stock has a market capitalization of $108.81 billion, a price-to-earnings ratio of 25.55, a P/E/G ratio of 1.43 and a beta of 0.38. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, sell-side analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.